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Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we
now report the long-term results of a phase II trial in advanced soft-tissue sarcomas. Forty-six patients with locally advanced or
metastatic soft-tissue sarcomas were included, with age o60 years and all except one in good performance status (0 or 1). The
chemotherapy treatment consisted of ifosfamide 10gm
 2 (continuous infusion for 5 days), doxorubicin 30mgm
 2day
 1 3 (total
dose 90mgm
 2), mesna and granulocyte-colony stimulating factor. Cycles were repeated every 21 days. A median of 4 (1–6) cycles
per patient was administered. Twenty-two patients responded to therapy, including three complete responders and 19 partial
responders for an overall response rate of 48% (95% CI: 33–63%). The response rate was not different between localised and
metastatic diseases or between histological types, but was higher in grade 3 tumours. Median overall survival was 19 months. Salvage
therapies (surgery and/or radiotherapy) were performed in 43% of patients and found to be the most significant predictor for
favourable survival (exploratory multivariate analysis). Haematological toxicity was severe, including grade X3 neutropenia in 59%,
thrombopenia in 39% and anaemia in 27% of cycles. Three patients experienced grade 3 neurotoxicity and one patient died of septic
shock. This high-dose regimen is toxic but nonetheless feasible in multicentre settings in non elderly patients with good performance
status. A high response rate was obtained. Prolonged survival was mainly a function of salvage therapies.
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Soft-tissue sarcomas are a highly heterogeneous group of tumours
with a low incidence. At least 50 different subtypes are
distinguished, each with its specific biology and clinical outcome.
The majority of these tumours are presumably derived from
mesoderm and categorised by the normal tissue they resemble. As
they are uncommon, however, they are subsumed under the
collective term soft-tissue sarcoma and therapeutically approached
in similar ways.
In recent years, progress has been made in understanding their
clinical and biological complexity (Dirix and Van Oosterom, 1999;
Fayette and Blay, 2005), such that oncologists have increasingly
been able to define customised therapies. Paclitaxel has been found
to be active mainly in patients with angiosarcomas (Fata et al,
1999). Docetaxel combined with gemcitabine has been shown to
induce a 53% response rate in leiomyosarcomas of gynaecological
origin (Hensley et al, 2002). Topoisomerase inhibitors are active
for rhabdomyosarcomas (Cosetti et al, 2002). Trabectedin (ET743)
has a low objective response rate but led to stable disease in 24% of
pretreated patients (Yovine et al, 2004) and was mainly active in
myxoid liposarcomas (Grosso et al, 2006).
The most common approach used in all histological subtypes,
however, is to use doxorubicin and ifosfamide (Edmonson et al,
1993). Their anti-tumour activity as single agents does not exceed
15–25%. Combining these agents might be more effective but has
not been shown to improve survival in a significant way compared
to their use as single agents (Santoro et al, 1995).
Following suggestions that these agents may have a dose–
response relationship (O’Bryan et al, 1973; Le Cesne et al,1 9 9 5 ;
Cerny et al, 1999), various phase-I and -II trials were performed in
which they were administered at high doses, yielding response rates
of 40–66% (Frustaci et al, 1997; Patel et al, 1998; Reichardt et al,
1998; Maurel et al, 2004a). In some studies, median overall survival
was up to 24 months. There are also suggestions that applying
regimens with high response rates may render an initially inoperable
tumour operable, thereby improving the outcome (Judson, 2004).
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sIn a previous study, we defined the maximum tolerated dose
of doxorubicin combined with ifosfamide, administered every 3
weeks and supported by haematopoietic growth factors (Leyvraz
et al, 1998). The maximum tolerated dose of doxorubicin was
60mgm
 2 with ifosfamide at 12gm
 2 and could be increased to
90mgm
 2 with ifosfamide at 10gm
 2. Myelosuppression was
severe but resolved within 4 days.
On this basis, we designed a multicentre nonrandomised phase-
II trial for advanced and metastatic soft-tissue sarcomas. Salvage
surgery and/or radiotherapy with the aim of removing all residual
tumour tissue was performed whenever such an approach was
considered appropriate to render patients free of disease.
PATIENTS AND METHODS
The protocol was in accordance with the Declaration of Helsinki
principles and was approved by the respective responsible ethics
commissions. All patients included in the study gave their written
informed consent.
Inclusion criteria
Patients with histologically demonstrated advanced or metastatic
soft-tissue sarcoma were eligible for the study. Excluded were
patients with histological evidence of malignant mesothelioma,
chondrosarcoma, neuroblastoma, osteosarcoma, Ewing sarcoma
and embryonal rhadomyosarcoma.
Additional eligibility criteria included the presence of measur-
able disease in one or two dimensions as demonstrated by physical
examination or imaging techniques. Ascites and pleural effusions
were not considered measurable. Patients were only included if
they were 18–70 years old and showed a performance status of p2
as defined by the Eastern Cooperative Oncology Group (ECOG)
(Oken et al, 1982). They were not included in the presence of
previous chemotherapy, previous radiotherapy on recurrent
disease, or CNS metastases. Another exclusion criterion was
abnormal haematological, renal or hepatic function. Cardiac
function was required to be within the normal range on
echocardiography or multigated nuclear scanning.
Study design and treatment plan
This was a multicentre, single-arm phase II trial (protocol SAKK
57/93). Chemotherapy cycles were repeated every 3 weeks as
follows: (i) ifosfamide 10gm
 2 i.v. as continuous infusion over 5
days; (ii) mesna 2gm
 2day
 1 i.v. as continuous infusion over 6
days; (iii) doxorubicin 30mgm
 2day
 1 i.v. bolus given for 3 days
(total dose 90mgm
 2), starting 4h after initiation of ifosfamide
on day 1; and (iv) granulocyte-colony stimulating factor (G-CSF,
Filgrastim) 5mgkg
 1 s.c. once daily as of day 6 for 10 days or – if
neutrophile counts were o500ml
 1 by that time – for a total of
14 days.
Response, toxicity assessment, dose modification and
pathology review
Response in up to three measurable lesions was assessed by
tumour evaluation according to standard WHO criteria (World
Health Organization, 1979). Each observed complete or partial
response had to be confirmed at least 4 weeks later. CT scans were
obtained at baseline, after every other chemotherapy cycle, and
at the end of the treatment. Toxicity was assessed based on WHO
grading, and neurotoxicity based on MD Anderson scores
(Castellanos and Fields, 1986).
Subsequent treatment cycles were delayed by 1 or 2 weeks if
o3500ml
 1 leukocytes or o100000ml
 1 platelets were measured
at day 22. Dose modifications were performed: (i) if i.v. antibiotics
were required during myelosuppression or in case of thrombo-
cytopenia-related bleeding, by reducing ifosfamide to 8gm
 2; (ii)
in the presence of WHO grade X3 mucositis, by reducing
doxorubicin to 75mgm
 2. The dose of doxorubicin was not
reduced after myelosuppression. Ifosfamide could be increased to
12gm
 2 after normal recovery from myelosuppression without
febrile episodes requiring the use of i.v. antibiotics. Dose intensity
was calculated in mgm
 2week
 1 for each patient (Hryniuk and
Goodyear, 1990).
In case the MD Anderson score was X2, an attempt was made to
manage the neurotoxic event by administering methylene blue
rather than decreasing the dose of ifosfamide. Methylene blue was
then administered as an i.v. bolus of 50mg repeated at the same
dose every 2h, or as continuous infusion at 200mgday
 1 diluted
in 5% dextrose, until the event resolved (Ku ¨pfer et al, 1994).
Cardiotoxicity was monitored by assessing cardiac ejection
fraction every 2–3 cycles and prior to chemotherapy cycles on
reaching doxorubicin cumulative doses of 4450mgm
 2.
Chemotherapy was discontinued if cardiac ejection fraction
dropped to o40%. Chemotherapy was not administered in
the presence of serum creatinine 4150mmoll
 1 or creatinine
clearance o60mlmin
 1.
Pathology specimens were reviewed by an independent group of
expert pathologists led by LG to confirm diagnosis and tumour
grade based on the FNCLCC grading system (Guillou et al, 1997).
Statistical methods
The primary end point of the study was the tumour response rate
based on WHO criteria. Simon’s optimal two-stage design was
used to calculate the number of patients to be included in the
phase-II trial, based on the premise that a response rate of o40%
would disqualify the treatment regimen, while a response rate
of X70% would render it a promising option. To obtain a
significance level of 5% at a power of 80%, a total number of 46
patients were required, with 16 of them in the stage-I and another
30 in the stage-II phase. After the first 16 patients had been
evaluated for their response to chemotherapy, it was decided that
the trial should be continued until the target number of 46 patients
was reached. At least 24 responses among the 46 patients were
required to consider the treatment promising.
Confidence intervals for response rates were calculated using the
Clopper–Pearson method. Time to progression was calculated for
all patients from the time of enrollment until disease progression
or death, with censoring at last follow-up. Survival times were
calculated from enrollment to death or last follow-up. The
Kaplan–Meier was used to estimate the median values of time to
progression and survival. Log-rank test was used to evaluate
differences in survival. Cox regression was used for exploratory
multivariate analysis of survival. The following variables, repre-
sented by appropriate binary indicators, were included in the
Cox regression: histology (leiomyosarcomas vs other), tumour
grade (3 vs other), response (complete/partial response vs other),
tumour location (localised vs metastatic disease) and salvage
therapy with curative intention (yes vs no).
RESULTS
Patient characteristics
Fifty-one patients with advanced soft-tissue sarcomas, from seven
SAKK (Swiss Group for Clinical Cancer Research) centres were
enrolled in the study between 10/1995 and 1/2001. As gastro-
intestinal stromal tumour (GIST) is now recognised as a specific
entity, it was decided to exclude patients with GIST from analysis.
On histopathological review, five patients were excluded from
analysis because of the following characteristics: melanoma,
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sprogressive disease after one cycle of the studied regimen (n¼1);
cystosarcoma phyllodes of the breast with metastases in the lung,
partial response after six cycles of treatment (n¼1); three GIST,
progression after two chemotherapy cycles (n¼2) and death due to
intestinal haemorrhage during the first chemotherapy cycle (n¼1).
Thus, a total of 46 patients (18 women and 28 men) could be
evaluated. Pertinent characteristics are summarised in Table 1.
The median age of these patients was 51 (21–60) years. Except one
patient had a compromised performance status WHO grade 2,
all the others had a WHO grade 0 or 1. Leiomyosarcomas and
malignant fibrohistiocytoma (MFH) were the most frequent
histologies, each accounting for almost one-third of all tumour
types. Tumours were grade 3 in 54% and grade 2 in 30% of
patients. The six patients with grade 1 tumour (13%) diagnosed on
the biopsy of the primary had distant metastases at time of
inclusion. While most patients were diagnosed with meta-
static tumours, one-third presented with advanced localised
disease (large peripheral primary¼5, inoperable primary¼4,
recurrences¼5).
Toxicity and dose intensity
A median of 4 (1–6) chemotherapy cycles per patient was
administered, and a total of 187 cycles were analysed for toxicity.
Myelosuppression was the predominant type of toxicity. Severe
neutropenia WHO Xgrade 3 was observed in 59% of cycles (73%
of patients being affected) and a febrile episode occurred in 29%
(with demonstrable infection in 20%) of cycles. One patient died of
septic shock during his fourth cycle. WHO Xgrade 3 thrombo-
cytopenia and anaemia were observed in 39 and 27% of cycles,
respectively, affecting two-third of patients.
Neurological toxicity (MD Anderson score) was observed during
11 cycles (grade 1: n¼8; grade 3: n¼3). All events could be
managed by administration of methylene blue and/or discontinua-
tion of ifosfamide. Transient elevations in creatinine levels were
observed in three patients. No cases of severe renal toxicity were
noted, although 17 cycles were associated with transient micro-
scopic haematuria. Mucositis occurred in 46% of cycles but
was generally moderate, reaching grade 3 or 4 in only 19 cycles
(10%). No cases of clinical heart failure were noted, although
two patients had significant drops in cardiac ejection fraction
from baseline. Doses were modified in 29% of cycles, invariably
because of toxicity. A total of 22% chemotherapy cycles
were delayed because of toxicity or upon patients’ request. The
dose intensity of ifosfamide could be maintained at a median of
2740mgm
 2week
 1 (82% of the planned dose) and for doxorubicin
at a median of 26mgm
 2week
 1 (86% of the planned dose).
Response and survival
Of the 46 patients who were evaluated for response to chemother-
apy, three were complete responders (6.5%) and 19 were partial
responders (41%). The overall response rate was thus 48% (98% CI:
33–63%). A total of 18 patients showed stable disease (39%), and
five patients showed progressive disease (11%). The response rate
was not different between localised and metastatic diseases (50
and 47%). A partial response was observed in two among the five
patients with large primaries. Broken up by histological tumour
types, overall response to chemotherapy was observed in 5/13
patients with leiomyosarcomas (38%, 95% CI: 14–68%), in 6/11
patients with malignant fibrohistiocytomas (54%, 95% CI: 23–
83%), in 4/4 patients with epithelioid sarcomas, in 3/4 patients with
angiosarcomas, in 1/4 patients with neurofibrosarcomas and in 0/4
patients with liposarcomas. Response rates were slightly higher
in grade 3 (14/25¼56%, 95% CI: 35–76%) than in grade 1–2
(8/20¼40%, 95% CI: 19–64%) tumours.
A total of 20 patients were treated by salvage surgery and/or
radiotherapy following partial response (n¼12) or stable disease
(n¼8) after chemotherapy. These salvage regimens included both
surgery and radiotherapy (n¼7), surgery (n¼2) or radiotherapy
(n¼1) in 10 patients with localised disease and surgery (n¼6) or
radiotherapy (n¼4) in 10 patients with metastatic disease.
After a median follow-up of 45 months, there were 31 cases of
tumour progression and 24 cases of tumour-related death. Other
causes of death included coronary artery disease (n¼1),
pulmonary embolism (n¼2), septic shock (n¼1) or remained
unknown (n¼3). Overall, our strategy yielded a median time to
progression of 16.2 months (95% CI: 10.2–22.5) and a median
overall survival of 19.6 months (95% CI: 14.2–25.5) (Figure 1).
Multivariate analysis including salvage therapy, histology, grade,
tumour localisation and response to chemotherapy as covariates
demonstrated that salvage therapy was the most significant
predictor for favourable outcomes (hazard ratio: 0.11; 95% CI:
0.04–0.30). Leiomyosarcomas were associated with significantly
better outcomes than all other histological tumour types (hazard
ratio: 0.27; 95% CI: 0.11–0.70). By contrast, tumour grade,
localisation and tumour response to chemotherapy had any
significant impact on survival (Figure 2).
DISCUSSION
In a previous phase I trial, we identified the maximum tolerated
dose levels for combined administration of ifosfamide and
Table 1 Patient characteristics
Number of patients 46
Sex
Male 28
Female 18
Performance status
02 4
12 1
21
Sarcoma type
Leiomyosarcoma 13
Malignant fibrous histiocytoma 11
Angiosarcoma 4
Epithelioid sarcoma 4
Liposarcoma 4
Neurofibrosarcoma 4
Unclassified 2
Alveolar rhabdomyosarcoma 1
Synoviosarcoma 1
Extra-skeletal osteosarcoma 1
Malignant hemangiopericytoma 1
Differentiation grade
16
21 4
32 5
Unknown 1
Tumour location
Localised 14
Metastatic 32
Lung 21
Lymph nodes 13
Liver 6
Bone 3
Soft tissue 3
Pancreas 1
Kidney 1
Peritoneum 1
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sdoxorubicin (Leyvraz et al, 1998). The phase II trial herein
presented was required to confirm the increased response rate
suggested in that previous trial. It has successfully accomplished
this purpose by demonstrating a response rate of 48% (95% CI:
33–63%) in 46 patients with advanced soft-tissue sarcomas.
Although this observed response rate did not reach the require-
ment being considered promising as defined by the statistical
design, it is in the range of similar response rates (40–66%) for
high-dose combination of ifosfamide and doxorubicin that have
been obtained in other phase-II studies (Frustaci et al, 1997; Patel
et al, 1998; Reichardt et al, 1998). The most recent trials have
yielded less impressive response rates (25–23%) but were designed
such that only one agent was administered at high dose levels
(Le Cesne et al, 2000; Worden et al, 2005). Indeed, the efficacy
of ifosfamide alone at standard dose (5gm
 2) was shown to be
minimal (10%) in a randomised trial (van Oosterom et al, 2002).
Moreover the best schedule of ifosfamide administration is still
unknown. There were suggestions that daily 2- to 4h-infusion
might be more active than continuous infusion (Patel et al, 1997),
but might be also more toxic (Antman et al, 1989).
As expected, and despite the use of haematopoietic growth
factors, the combined myelotoxicity of both agents employed
in our study led to severe (WHO grade 3–4) neutropenia in
59% of cycles and 73% of patients. These episodes were of short
duration. Febrile neutropenia occurred in 29% of cycles. One
patient died of septic shock. Severe anaemia and thrombopenia
were observed in two-thirds of patients. Based on our results, we
conclude that these toxic events can be managed in a multicentre
setting if adequate experience is available in the participating
centres, but limited to patients aged p60 years and with a
performance status o2.
Similar toxicity profiles, with severe neutropenia in 94–100% of
patients, were described in other trials (Patel et al, 1998; Reichardt
et al, 1998). Lower-dose combinations led to severe neutropenia in
87–90% and severe infection in 17% of patients (Le Cesne et al,
2000; Worden et al, 2005). One of these studies involved two toxic
deaths out of 40 patients, severe thrombopenia in 50–62% and
severe anaemia in approximately 50% of patients (Worden et al,
2005). Even standard dose levels (ifosfamide 6gm
 2 and
doxorubicin 60mgm
 2 and G-CSF) led to severe neutropenia in
49%, anaemia in 23%, and thrombopenia in 15% of patients
(Worden et al, 2005). In a large-scale EORTC trial, dose levels of
ifosfamide 5gm
 2 and doxorubicin 50mgm
 2 but without G-CSF
led also to severe neutropenia in 86%, and thrombopenia in 8% of
patients (Le Cesne et al, 2000).
It is thus reasonable to conclude that myelosuppression should
be accepted as inherent in any ifosfamide-doxorubicin combina-
tion therapy. Therefore, these regimens should only be adminis-
tered in specialised centres (Benjamin, 1987). If severe toxicity is
the price to be paid for improved outcomes, it might be acceptable
after all.
Median overall survival in the present study was 19.6 months,
with an estimated 5-year-survival rate of 30%. These results are
comparable with overall survival times of 18–25 months reported
in other intensive-dose trials (Frustaci et al, 1997; De Pas et al,
1998; Reichardt et al, 1998). They are presumably also better than
the 12 months obtained in standard-dose trials, even though the
respective data may not be suitable for direct comparisons
(Bramwell et al, 2003). The exploratory multivariate analysis
defined that leiomyosarcoma had a better outcome compared to
other histology subtypes. The prognostic value on survival of the
different histologies is yet unsettled. When standard chemotherapy
is used, the median overall survival was improved for liposarcoma
(Van Glabbeke et al, 1999), but 5-year survivors could be found
equally in all subtypes (Blay et al, 2003). If leiomyosarcomas have a
very low response rate (10%) with standard chemotherapy, in our
small series, as well as in other similar ones, the response rates
ranged between 30 and 75% (Frustaci et al, 1997; Reichardt et al,
1998; Maurel et al, 2004b), potentially explaining an improved
outcome.
The objection may be raised that our results were only possible
because we selected patients with favourable prognostic factors
and good performance status who were in a particularly good
condition to tolerate such an intensive and toxic approach (Van
Glabbeke et al, 1999). While this may be true, the EORTC has
demonstrated (based on 4% of 1888 patients) that complete
remission is not just a yardstick for chemotherapeutic success but
is really the most important predictor of favourable long-term
survival (Blay et al, 2003).
Trials in which high-dose ifosfamide was combined with high-
dose anthracylines have yielded complete remission rates of
8–20% (Reichardt et al, 1998). In our study it was 6.5% and might
have accounted only marginally to the final results. However, a
complete remission should not be solely based on chemotherapy.
Salvage surgery performed after chemotherapy should also be taken
into account, since patients in whom all residual disease is
surgically removed will do equally well (Reichardt et al, 1998). In
117 patients that have been operated in order to render them
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Figure 1 Kaplan–Meier curve for overall survival (interrupted line 95%
confidence interval).
0.0
0.2
0.4
0.6
0.8
1.0
01 2 2 4 3 6 4 8 6 0 7 2
Salvage treatment
No salvage treatment
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
Months
Number at risk (salvage/no salvage treatment):
20 18 14 8 7 5 3
26 15 3 1 0 0 0
Figure 2 Overall survival of patients treated by salvage surgery and/or
radiotherapy (aiming to eliminate all residual disease) in addition to
chemotherapy vs patients treated by high-dose chemotherapy only.
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swithout evidence of disease, a median overall survival of 19 months
was obtained (Billingsley et al, 1999). In previous studies of high-
dose chemotherapy, salvage surgery with or without radiotherapy
could be performed in 17–32% of patients and may have
contributed to the improved outcomes in these series.
With these considerations in mind, high-dose chemotherapy
with G-CSF support could be defined as part of a multidisciplinary
strategy in the treatment of soft-tissue sarcomas, to be performed
at experienced institutions only. Its goal would be to induce the
most effective antitumour response available, thereby preparing
the ground for salvage therapies to improve the outcome further.
And future research should focus on identifying patients that
might benefit form such a combined treatment approach.
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